“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...

In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, ...

Please provide your email address to receive an email when new articles are posted on . Serious infections in patients with chronic lymphocytic leukemia have doubled despite increased use of ...

For people living with primary immunodeficiency (PI), immunoglobulin replacement therapy (Ig) is a cornerstone of treatment. It helps prevent serious infections, reduces hospitalizations, and supports ...

Immunoglobulin replacement therapy (IgRT) represents a pivotal intervention in managing secondary immunodeficiency, a complication arising from treatments or underlying conditions that impair the body ...

(WASHINGTON, July 31, 2025) — In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious ...

Intravenous immunoglobulin therapy (IVIG) is a critical treatment modality in the management of a spectrum of immunodeficiencies, autoimmune disorders, and inflammatory conditions. Derived from pooled ...

Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] ...

CLL, a common type of leukemia in adults, disrupts the body's production of antibodies (immunoglobulin molecules) that fight infections. As a result, patients with CLL are often susceptible to serious ...

GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Approved for Intravenous or Subcutaneous Use in People Aged Two and Older with ...